SLDB.US Solid Biosciences LLC

Healthcare Biotechnology USA Stocks
6.23 USD
Close of Nov 17, 2026
4.44 11.45
Market cap
USD 695M
P/E
-
P/B
2.12x
ROE
-64.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SLDB.US undervalued?

Graham number

The Graham number of Solid Biosciences LLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Solid Biosciences LLC fundamental analysis

No fundamental analysis for Solid Biosciences LLC yet.

Solid Biosciences LLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Solid Biosciences LLC

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilat…

Full company profile